U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H11NO
Molecular Weight 185.2218
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIRFENIDONE

SMILES

CC1=CN(C(=O)C=C1)C2=CC=CC=C2

InChI

InChIKey=ISWRGOKTTBVCFA-UHFFFAOYSA-N
InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3

HIDE SMILES / InChI
Molecular Formula C12H11NO
Molecular Weight 185.2218
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=12010989; http://www.ncbi.nlm.nih.gov/pubmed/?term=9435445; https://en.wikipedia.org/wiki/Pirfenidone

Pirfenidone is a synthetic antifibrotic agent indicated for the treatment of idiopathic pulmonary fibrosis as Esbriet. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors. It also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. Pirfenidone has demonstrated activity in multiple fibrotic conditions however the exact mechanism of action of pirfenidone in the treatment of IPF has not been established.

CNS Activity

Originator

Approval Year

2014
450
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8360
ESBRIET

Approved Use

Indicated for the treatment of idiopathic pulmonary fibrosis

Launch Date

1.42611841E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6560 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/28808905
801 mg single, oral
dose: 801 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PIRFENIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
98000 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/28808905
801 mg single, oral
dose: 801 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PIRFENIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.75 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/28808905
801 mg single, oral
dose: 801 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PIRFENIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
3 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
PIRFENIDONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
42%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
PIRFENIDONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
Disc. AE: Rash, Nausea...
AEs leading to
discontinuation/dose reduction:
Rash (1.3%)
Nausea (1.1%)
Rash (3%)
Nausea (3%)
Diarrhea (3%)
Photosensitivity reaction (3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Disc. AE: Weight decreased, Photosensitivity reaction...
AEs leading to
discontinuation/dose reduction:
Weight decreased (0.8%)
Photosensitivity reaction (0.6%)
Respiratory failure (0.5%)
Hepatic enzyme increased (0.5%)
Bladder cancer (0.5%)
Vomiting (0.3%)
GERD (0.3%)
Malaise (0.3%)
Dysgeusia (0.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
AEs

AEs

AESignificanceDosePopulation
Nausea 1.1%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
Rash 1.3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
Diarrhea 3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
Nausea 3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
Photosensitivity reaction 3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
Rash 3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
Dysgeusia 0.3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
GERD 0.3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Malaise 0.3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Vomiting 0.3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Bladder cancer 0.5%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Hepatic enzyme increased 0.5%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Respiratory failure 0.5%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Photosensitivity reaction 0.6%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Weight decreased 0.8%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1579

inducer
768
substrate
1010

inhibitor
1752

inducer
383
substrate
1193

inhibitor
1837

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1509

CYP2A6
704

CYP2C19
1463

CYP2E1
876

CYP2C8
901

CYP3A4/5
273

P-gp
1437
CYP1A2
1032

CYP1A1
348

CYP2A6
523

CYP2B6
660

CYP2C8
688

CYP2C18
139

CYP2C19
985

CYP2E1
648

CYP2J2
56

P-gp
1527
CYP3A
126

CYP2C19
290

CYP3A4/5
120

CYP1A2
689
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1673
 no
5-carboxy-pirfenidone
1
CYP1A2
1673
 no
5-carboxy-pirfenidone
1
CYP2A6
736
 no
5-carboxy-pirfenidone
1
CYP2C19
1537
 no
5-carboxy-pirfenidone
1
CYP2C19
1537
 no
5-carboxy-pirfenidone
1
CYP2C8
955
 no
5-carboxy-pirfenidone
1
CYP2C9
1803
 no
CYP2C9
1803
 no
5-carboxy-pirfenidone
1
CYP2C9
1803
 no
5-carboxy-pirfenidone
1
CYP2D6
1875
 no
5-carboxy-pirfenidone
1
CYP2E1
964
 no
5-carboxy-pirfenidone
1
CYP3A4
1909
 no
5-carboxy-pirfenidone
1
CYP3A4/5
330
 no
CYP3A4/5
330
 no
5-carboxy-pirfenidone
1
P-gp
1626
 weak [IC50 >1000 uM]
CYP1A2
1673
 yes [Inhibition 1000 uM]
CYP2A6
736
 yes [Inhibition 1000 uM]
CYP2C19
1537
 yes [Inhibition 1000 uM]
CYP2C9
1803
 yes [Inhibition 1000 uM]
CYP2D6
1875
 yes [Inhibition 1000 uM]
CYP2E1
964
 yes [Inhibition 1000 uM]
CYP3A4
1909
 yes [Inhibition 1000 uM]
CYP2C19
1537
 yes
CYP3A
295
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1032
 major
yes (co-administration study)
Comment: In a single-dose drug interaction study in 25 healthy nonsmokers and 25 smokers, ESBRIET was coadministered with fluvoxamine (50 mg at bedtime for 3 days; 50 mg twice a day for 3 days, and 50 mg in the morning and 100 mg at bedtime for 4 days). An approximately 4-fold increase in exposure to pirfenidone in nonsmokers and approximately 7-fold increase in exposure in smokers was observed.
Page: 6.0
CYP1A1
348
 yes
CYP2A6
523
 yes
CYP2B6
660
 yes
CYP2C18
139
 yes
CYP2C19
985
 yes
CYP2C8
688
 yes
CYP2C9
1010
 yes
CYP2D6
1193
 yes
CYP2E1
648
 yes
CYP2J2
56
 yes
P-gp
1527
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:32016
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:32016
ChemicalBook
CB5299210
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5299210
MolPort
MolPort-003-666-737
https://www.molport.com/shop/molecule-link/MolPort-003-666-737
Selleck Chemicals
pirfenidone
http://www.selleckchem.com/products/pirfenidone.html
ZINC
ZINC000000001958
http://zinc15.docking.org/substances/ZINC000000001958
eMolecules
593320
https://www.emolecules.com/cgi-bin/more?vid=593320
PubMed

PubMed

TitleDatePubMed
Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice.
2001 Aug 24
A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia.
2001 Jul
Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats.
2001 Jul
The balance between collagen synthesis and degradation in diffuse lung disease.
2001 Mar
Idiopathic pulmonary fibrosis: current and future treatment options.
2002
Growth factors in idiopathic pulmonary fibrosis: relative roles.
2002
Effect of pirfenidone against vanadate-induced kidney fibrosis in rats.
2002 Aug 1
Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.
2002 Dec
Pirfenidone effectively reverses experimental liver fibrosis.
2002 Dec
Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B.
2002 Jun
Pirfenidone inhibits early myointimal proliferation but has no effect on late lesion size in rats.
2002 Mar
Gateways to clinical trials.
2002 Nov
Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production.
2002 Nov
Gateways to clinical trials.
2002 Oct
[Treatment of pulmonary fibrosis].
2002 Oct 19
Modulation of articular chondrocyte activity by pirfenidone.
2003
Gateways to clinical trials.
2003 Dec
Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy.
2004 Aug
Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats.
2004 Feb
Pirfenidone prevents endotoxin-induced liver injury after partial hepatectomy in rats.
2004 Jan
Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents.
2004 Jul-Aug
New perspectives in treatment of glomerulonephritis.
2004 Mar
Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model.
2004 Mar 15
Gateways to clinical trials.
2004 May
Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1beta at a step of NF-kappaB DNA binding in hepatocytes.
2004 Nov
Effect of pirfenidone on induction of chemokines in rat hepatocytes.
2004 Sep
Pirfenidone protects endotoxin-induced liver injury after hepatic ischemia in rats.
2004 Sep
A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis.
2005 Apr
Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity.
2005 Feb 27
Retardation of kidney failure -- applying principles to practice.
2005 Jan
The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity.
2005 May 15
Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation.
2005 Nov
Gateways to clinical trials.
2005 Oct
Symptomatic and disease-modifying therapies for multiple sclerosis: recent developments: highlights of the 9th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis, October 3, 2004, Toronto, Ontario, Canada.
2005 Winter
Pirfenidone and chronic progressive obliterative airway disease.
2006 Apr
Simple determination of pirfenidone in rat plasma via high-performance liquid chromatography.
2006 Dec
Current perspectives on the treatment of idiopathic pulmonary fibrosis.
2006 Jun
[Newly developed therapeutic drugs for idiopathic interstitial pneumonias].
2006 Jun 10
Therapeutic management of idiopathic pulmonary fibrosis: an evidence-based approach.
2006 Mar
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
2011 May 21
Patents

Patents

JP2010120912A
1
US6211209
1
US6261537
11
US6264917
2
US6300349
1
US6323236
11
US6331289
5

Sample Use Guides

In Vivo Use Guide
The recommended daily maintenance dosage is 801 mg (three 267 mg capsules) three times a day with food for a total of 2403 mg/day. Doses should be taken at the same time each day. Upon initiation of treatment, titrate to the full dosage of nine capsules per day over a 14-day period as follows: 1 capsule three times days 1 through 7; 2 capsules three times a day days 8 through 14; 3 capsules three times a day days 15 onward.
Route of Administration: Oral
In Vitro Use Guide
0.01, 0.1, 0.3, and 1.0 mg/mL in in cultured myometrial and leiomyoma smooth muscle cells.
Substance Class Chemical
Created
by admin
on Thu Jul 06 00:31:24 UTC 2023
Edited
by admin
on Thu Jul 06 00:31:24 UTC 2023
Record UNII
D7NLD2JX7U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIRFENIDONE
DASH   EMA EPAR   INN   JAN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
5-Methyl-1-phenyl-2(1H)-pyridone
Systematic Name English
PIRFENIDONE [USAN]
Common Name English
PIRFENIDONE [MART.]
Common Name English
2(1H)-PYRIDINONE, 5-METHYL-1-PHENYL-
Systematic Name English
PIRFENIDONE [EMA EPAR]
Common Name English
PIRFENIDONE [EP MONOGRAPH]
Common Name English
PIRFENIDONE [JAN]
Common Name English
PIRFENIDONE COMPONENT OF ESBRIET
Brand Name English
Pirfenidone [WHO-DD]
Common Name English
PIRFENIDONE [ORANGE BOOK]
Common Name English
pirfenidone [INN]
Common Name English
ESBRIET
Brand Name English
ESBRIET COMPONENT PIRFENIDONE
Brand Name English
PIRFENIDONE [VANDF]
Common Name English
PIRFENIDONE [MI]
Common Name English
AMR-69
Code English
PIRESPA
Brand Name English
NSC-748456
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 727219
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
EU-Orphan Drug EU/3/04/241
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
FDA ORPHAN DRUG 436914
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
EMA ASSESSMENT REPORTS ESBRIET (AUTHORISED: IDIOPATHIC PULMONARY FIBROSIS)
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
NDF-RT N0000191420
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
NCI_THESAURUS C257
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
NCI_THESAURUS C797
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
WHO-ATC L04AX05
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
FDA ORPHAN DRUG 177903
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
WHO-VATC QL04AX05
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
FDA ORPHAN DRUG 411113
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C2635
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
FDA UNII
D7NLD2JX7U
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
DRUG CENTRAL
4224
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
INN
3825
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
ChEMBL
CHEMBL1256391
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
IUPHAR
7532
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
MERCK INDEX
M8876
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY Merck Index
WIKIPEDIA
PIRFENIDONE
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
PUBCHEM
40632
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
MESH
C093844
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
EPA CompTox
DTXSID4045183
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
HSDB
8340
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
DAILYMED
D7NLD2JX7U
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
CHEBI
32016
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
RXCUI
1592254
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY RxNorm
EVMPD
SUB09907MIG
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
CAS
53179-13-8
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
NDF-RT
N0000007575
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY Pyridones [Chemical/Ingredient]
DRUG BANK
DB04951
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
SMS_ID
100000081645
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
JAPANESE REVIEW
PIRESPA
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY APPROVED OCTOBER 2008
NSC
748456
Created by admin on Thu Jul 06 00:31:24 UTC 2023 , Edited by admin on Thu Jul 06 00:31:24 UTC 2023
PRIMARY
Related Record Type Details
Structure of Deupirfenidone
LABELED -> NON-LABELED
CYTOCHROME P450 1A2
METABOLIC ENZYME -> SUBSTRATE
MAJOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of 5-CARBOXY-PIRFENIDONE
METABOLITE INACTIVE -> PARENT
In vitro profiling studies in hepatocytes and liver microsomes have shown that ESBRIET is primarily metabolized in the liver by CYP1A2 and multiple other CYPs (CYP2C9, 2C19, 2D6, and 2E1).
MAJOR
PLASMA; URINE
Related Record Type Details
Structure of PIRFENIDONE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC MULTIPLE DOSE ADMINISTRATION

Tmax PHARMACOKINETIC ORAL ADMINISTRATION

SINGLE DOSE

Tmax PHARMACOKINETIC FED CONDITION

HIGH-FAT MEAL

Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966